Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Revenue Growth 20pctResults View source PDF Explain this filing

MEDICO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹39.22

prior close

₹39.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-1.8% vs market

Pharmaceuticals peers, median of 148sector+0.3%-1.9% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.0

10m

-1.4

15m

-1.4

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6+0.2-1.8+0.3-1.9

Next day

-0.7+0.2-0.9+0.3-1.0

+6.6+0.9+5.7+0.6+6.0

+4.8+0.1+4.7-0.3+5.1

+8.0+1.6+6.3+0.4+7.6

+6.9+2.8+4.1+0.6+6.4

+3.3+3.0+0.2+0.6+2.7

15d

+3.0+2.8+0.2+0.1+2.9

-0.6+3.1-3.6+1.5-2.0

+24.4+1.4+23.0-1.6+26.0

+36.8+1.4+35.4-4.4+41.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medico Remedies Limited submitted its Q1 FY26 standalone financial results for the quarter ended June 30, 2025, along with an unmodified limited review report from auditors V J Shah & Co. Revenue from operations rose to Rs. 3,825.15 lakhs from Rs. 3,079.81 lakhs in the same quarter last year, a year-on-year growth of about 24%. Profit after tax increased to Rs. 181.83 lakhs (vs Rs. 157.89 lakhs in Q1 FY25), translating to a basic EPS of Rs. 0.22. The company is heavily export-oriented, with overseas sales of Rs. 3,245.01 lakhs accounting for the bulk of revenue. Additionally, Mr. Hasan Bohra resigned as Company Secretary & Compliance Officer effective August 8, 2025, citing other professional commitments.

Likely market impact

Strong revenue growth and steady profitability suggest the company is expanding well, though the PAT growth of around 15% lagged the topline surge, indicating some margin pressure. The simultaneous exit of the Company & Compliance Officer is a minor governance event investors should watch for timely replacement.